Novel potent and selective thrombin inhibitors based on a central 1,4-benzoxazin-3(4H)-one scaffold

Journal of Medicinal Chemistry

Volumn 51, Issue 9, 2008, Pages 2863-2867

  Ilaš, Janez ^a   Tomašić, Tihomir ^a   Kikelj, Danijel ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [BENZYL[2 (4 CARBAMIMIDOYLBENZYL) 4 METHYL 3 OXO 3,4 DIHYDRO 2H 1,4 BENZOXAZIN 7 YI]AMINO] 2 OXOACETIC ACID; 3 [BENZYL[2 (4 CARBAMIMIDOYLBENZYL) 4 METHYL 3 OXO 3,4 DIHYDRO 2H 1,4 BENZOXAZIN 7 YL]AMINO] 3 OXOPROPANOIC ACID; BENZAMIDINE DERIVATIVE; BENZOXAZINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; ETHYL 2 [BENZYL[2 (4 CARBAMIMIDOYLBENZYL) 4 METHYL 3 OXO 3,4 DIHYDRO 2H 1,4 BENZOXAZIN 7 YL]AMINO] 2 OXOACETATE TRIFLUOROACETATE; THROMBIN; THROMBIN INHIBITOR; TRYPSIN;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

BENZOXAZINES; FACTOR XA; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; TRYPSIN; TRYPSIN INHIBITORS;

EID: 42949113013     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701622y     Document Type: Article

References (21)

1. Lopez, A. D.; Mathers, C. D.; Ezzati, M.; Jamison, D. T.; Murray, C. J. L. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006, 367, 1747-1757.
2. Schwienhorst, A. Direct thrombin inhibitors - A survey of recent developments. Cell. Mol. Life Sci. 2006, 63, 2773-2791.
3. Hijikata-Okunomiya, A.; Okamoto, S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin. Thromb. Hemostasis 1992, 18, 135-149.
4. Crowther, M. A.; Weitz, J. I. Ximelagatran: The first oral direct thrombin inhibitor. Expert Opin. Invest. Drugs 2004, 13, 403-413.
5. Casimiro-Garcia, A.; Dudley, D. A.; Heemstra, R. J.; Filipski, K. J.; Bigge, C. F.; Edmunds, J. J. Progress in the discovery of factor Xa inhibitors. Expert Opin. Ther. Pat. 2006, 16, 119-145.
6. Lazarus, R. A.; Olivero, A. G.; Eigenbrot, C.; Kirchhofer, D. Inhibitors of tissue factor/factor VIIa for anticoagulant therapy. Curr. Med. Chem. 2004, 11, 2275-2290.
7. Kranjc, A.; Kikelj, D.; Peterlin-Mašič, L. Recent advances in the discovery of tissue factor/factor VIIa inhibitors and dual inhibitors of factor VIIa/factor Xa. Curr. Pharm. Des. 2005, 11, 4207-4227.
8. Anderluh Štefanič, P.; Anderluh, M.; Ilaš, J.; Mravljak, J.; Sollner Dolenc, M.; Stegnar, M.; Kikelj, D. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities. J. Med. Chem. 2005, 48, 3110-3113.
9. Peterlin-Mašič, L.; Kikelj, D. Arginine mimetics. Tetrahedron 2001, 57, 7073-7105.
10. Hauel, N. H.; Nar, H.; Priepke, H.; Ries, U.; Stassen, J-M.; Wienen, W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem. 2002, 45, 1757-1766.
11. Has, J.; Kikelj, D. Ring opening of 2-benzylamino-2H-1,4- benzoxazin-3(4H)-ones and 2-bromo-2H-1,4-benzoxazin-3(4H)- ones. Helv. Chim. Acta, in press.
12. Roger, R.; Neilson, D. G. The chemistry of imidates. Chem. Rev. 1961, 61, 179-211.
13. Sagi, K.; Nakagawa, T.; Yamanashi, M.; Makino, S.; Takahashi, M.; Takayanagi, M.; Takenaka, K.; Suzuki, N.; Oono, S.; Kataoka, N.; Ishikawa, K.; Shima, S.; Fukuda, Y.; Kayahara, T.; Takehana, S.; Shima, Y.; Tashiro, K.; Yamamoto, H.; Yoshimoto, R.; Iwata, S.; Tsuji, T.; Sakurai, K.; Shoji, M. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-Substituted-4-amidinophenyl)pyruvic and -propionic acids. J. Med. Chem. 2003, 46, 1845-57.
14. Shaw, K. J.; Guilford, W. J. L.; Griedel, B. D.; Sakata, S.; Trinh, L.; Wu, S.; Xu, W.; Zhao, Z.; Morrissey, M, M. Benzimidazole-based fXa inhibitors with improved thrombin and trypsin selectivity. Bioorg. Med. Chem. Lett. 2002, 12, 1311-1314.
15. Kastenholz, M. A.; Pastor, M.; Cruciani, G.; Haaksma, E. E.; Fox, T. GRID/CPCA: A new computational tool to design selective ligands. J. Med. Chem. 2000, 43, 3033-3044.
16. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
17. Banner, D. W.; Hadvary, P. Crystallographic analysis at 3.0 Å resolution of the binding to human thrombin of 4 active site-directed inhibitors. J. Biol. Chem. 1991, 266, 20085-20093.
18. Lee, L.; Kreutter, K. D.; Pan, W.; Crysler, C.; Spurlino, J.; Player, M. R.; Tomczuk, B.; Lu, T. 2-(2-Chloro-6-fiuorophenyl)acetamides as potent thrombin inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 6266-6269.
19. Hilpert, K.; Ackermann, J.; Banner, D. W.; Gast, A.; Gubernator, K.; Hadvary, P. Design and synthesis of potent and highly selective thrombin inhibitors. J. Med. Chem. 1994, 37, 3889-3901.
20. 50) of an enzymatic-reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
21. i and inhibitor type from the concentration of inhibitor for 50-percent inhibition for Michaelis-Menten enzymes. Biochem. Med. Metab. Biol. 1987, 37, 344-349.